Opinion · 5 Jun 2025
Research articlePublished 2016
On Selection of Margin in Non-Inferiority Trials
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
In clinical trials, it is unethical to use a placebo control in treating patients with severe or life-threatening diseases such as cancer when approved and effective therapies (e.g., standard of care or active control agents) are available. Alternatively, an active control or non-inferiority trial is often considered. In practice, one of the key issues for a noninferiority trial is the determination of non-inferiority margin which has an impact on the power analysis for sample size calculation. In its 2010 draft guidance, the United States Food and Drug Administration (FDA) recommend a couple of margins for testing non-inferiority of a test treatment as compared to an active control agent or a standard of care treatment. In this article, several margins, which not only adjust for variability associated with the observed data but also take into consideration of the retention rate of the treatment effect, are proposed.
Keywords
Subjects
Mathematics & StatisticsAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Editorial · 31 Mar 2022
Equivalence and Non-inferiority Trials of CAM
Editorial · 20 Sep 2021
Streamlined Genetic Education Is Effective In Preparing Women Newly Diagnosed With Breast Cancer for Decision-Making About Treatment-Focused Genetic Testing: A Randomized Controlled Non-Inferiority Trial
Conference abstract · 18 Mar 2019
A randomized, double-blind, comparative, phase III, non-inferiority clinical trial between triamcinolone acetonide nasal spray (TAA) and fluticasone propionate nasal spray (FP) in adults suffering from perennial allergic
Conference abstract · 27 Jul 2018
Comparison of three sample size estimation methods for non-inferiority vaccine trials with multiple continuous co-primary endpoints
More from this journal
The newest in Journal of Biometrics & Biostatistics.
Article · 29 Dec 2025
Biometrics Enhance EHR Security and Patient Safety
Article · 29 Dec 2025
Biometric and Clinical Data for Enhanced Risk Prediction
Article · 29 Dec 2025
Advanced Statistics for Precision Public Health Innovations
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Biometrics & Biostatistics
- SubjectMathematics & Statistics
- BylineArticles whose byline prints “Shein-Chung Chow”
- BylineArticles whose byline prints “Fuyu Song”

